Low-dose versus High-dose Carfilzomib with Dexamethasone (S1304) in Patients with Relapsed-Refractory Multiple Myeloma.

CONCLUSIONS: This randomized trial did not support a benefit of fixed-duration, twice-weekly 56 mg/m2 dosing of carfilzomib over the 27 mg/m2 dose for the treatment of relapsed and/or refractory MM. However, treatment to progression in earlier patient populations with high-dose carfilzomib using different schedules should still be considered as part of the standard of care.
PMID: 32299820 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 15, 2020 Category: Cancer & Oncology Authors: Ailawadhi S, Sexton R, Lentzsch S, Abidi MH, Voorhees PM, Cohen AD, Rohren EM, Heitner S, Kelly K, Mackler NJ, Baer DM, Hoering A, Durie B, Orlowski RZ Tags: Clin Cancer Res Source Type: research